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between Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es 
Salaam, Tanzania and the University of Bergen in Norway aiming at faculty building 
at MUHAS. The project was performed within the Heart in Hypertension research 
group at the Institute of Medicine, University of Bergen. The Bergen Heart in 
Hypertension research group is chaired by professor Eva Gerdts and currently 
includes 1 professor, 1 professor emeritus, 3 post-doctoral fellows, 5 Ph.D. fellows 
and 2 research medical students. The research group has specialized in post-
processing echocardiographic images by data programs in large clinical studies 
focusing on changes in myocardial structure and function in cardiovascular disease, 
in particular during chronic pressure overload. The research group has national 
collaborations with the University of Tromsø and the University of Oslo and a large 
international network with repeated exchange of junior and senior researchers 
creating a pulsating international environment. The main international partners are 
Weill Medical College, Cornell University, New York, USA (Professor Richard B. 
Devereux) and Federico II University, Napoli, Italy (Professor Giovanni de Simone).  
The Echocardiography Research Laboratory at the Institute of Medicine, University 
of Bergen is DICOM based and fully digitalized with up-to-date equipment for 
analyses of all echocardiographic modalities including conventional 
echocardiography, deformation analysis by speckle tracking and three-dimensional 
echocardiography. Dedicated equipment for tissue Doppler analysis of myocardial 
mechanics is also available. The research group gives courses in echocardiography 
for medical students twice a year. The research fellows are included as teachers on 
these courses. An annual course for fellows under specialization in internal medicine 
or cardiology is also given. The latter is compulsory for obtaining board certification.  
The Echocardiography Research Laboratory is well integrated within the Unit for 
Non-invasive Cardiac Imaging at Department of Heart Disease, Haukeland 
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University Hospital, providing an excellent basis for integrated training in clinical 
echocardiography and scientific utilization of echocardiographic images. The 
Echocardiographic research laboratory has served as a core laboratory in large 
multicenter studies involving thousands of patients. 
The present project was initiated by the candidate, Pilly M. Chillo who had trained in 
echocardiography at the Department of Heart Disease at Haukeland University 
Hospital during specialization in cardiology. The project was funded by the Quota 
program through the Centre for International Health and by the Bergen Heart in 
Hypertension research group. All data collection took place at Muhimbili National 
Hospital in Dar es Salaam under supervision of co-mentor Dr. Johnson Lwakatare, 
Chief of Cardiology at the Department of Internal Medicine, MUHAS. All data 
analysis, the compulsory Ph.D. program and scientific writing took place at the 
University of Bergen, supervised by professor Eva Gerdts.    
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Abstract 
From echocardiographic studies in hypertension, African Americans have been found 
to be more prone to develop cardiac target-organ damage than Caucasians. 
Hypertension is among the major upcoming health problems in Africa. However, 
there is a lack of knowledge about cardiac structural and functional changes in 
hypertension and diabetes in native sub-Saharan Africans.  
This thesis consists of 3 studies that aimed at determining the prevalence, covariates 
and functional consequences of abnormal left ventricular (LV) geometry in native 
Tanzanian patients with hypertension and diabetes attending out-patient clinics at 
Muhimbili National Hospital in Dar es Salaam, Tanzania. In study I, 161 untreated 
hypertensive patients, and 80 age- and sex-matched normotensive controls were 
studied. Studies II and III included 123 type 2 and 61 type 1 diabetic patients with 
about 10 years duration of diabetes.  
The prevalence of abnormal LV geometry was 77% in type 2 diabetic patients, 62.1% 
in untreated hypertensives, 40% in type 1 diabetic patients and 12.5% among the 
controls. Concentric LV hypertrophy was the most common abnormal LV geometric 
pattern in type 2 diabetes (in 47% of patients with abnormal LV geometry) and in 
untreated hypertensive patients (in 42% of patients with abnormal LV geometry), 
while concentric remodelling was the predominant type of abnormal LV geometry in 
type 1 diabetic patients (in 75% of patients with abnormal LV geometry) and in 
controls (90% of controls with abnormal LV geometry). Higher systolic blood 
pressure, obesity and impaired renal function were the main independent 
determinants of abnormal LV geometry both in patients with hypertension and in 
diabetes. Abnormal LV geometry was associated with subclinical LV myocardial 
systolic dysfunction both in hypertension and in diabetes, as well as subclinical LV 
diastolic dysfunction independent of clinical covariates.  
A risk score comprising key clinical variables in standard assessment of diabetic 
patients (type of diabetes, hypertension, obesity and abnormal albuminuria) was 
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developed. This score demonstrated that presence of either hypertension, obesity or 
abnormal albuminuria in a patient with type 2 diabetes or presence of any 2 of these 
clinical variables in a type 1 diabetic patient identified 3 out of 4 diabetic patients 
with echocardiographic abnormal LV geometry (concentric remodelling or concentric 
LV hypertrophy, the main types of abnormal LV geometry in the diabetic patients).  
The ability of enlarged left atrial volume index (LAVI) to detect subclinical LV 
diastolic dysfunction in diabetic patients was tested, and was found to be a good 
indicator of LV diastolic dysfunction in type 2 diabetic patients while LAVI reflected 
early diabetic cardiomyopathy in type 1 diabetic patients. 
In conclusion, abnormal LV geometry is very prevalent in asymptomatic Tanzanian 
patients with hypertension and/or diabetes, increased by 4-6 folds compared to 
healthy controls, and is associated with subclinical LV systolic and diastolic 
dysfunction.  
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1. INTRODUCTION 
1.1 Hypertension and diabetes in a global health 
perspective 
Hypertension and diabetes are major risk factors for cardiovascular disease, the 
leading cause of deaths worldwide.1 In 2008, cardiovascular diseases alone were 
responsible for more than 17 million deaths globally.1 Although the incidence of 
cardiovascular diseases has been declining in some high-income countries over the 
past two decades, it has increased at a fast rate in low- and middle-income countries.1 
The World Health Organization has ranked hypertension among the 3 top health 
problems in the world, including in Africa.2 
The prevalence of hypertension is estimated to be 40% among adult general 
population globally, with the World Health Organization Africa region having the 
highest prevalence of around 46%.3 In people with hypertension, the risk of 
cardiovascular diseases doubles for each incremental increase of 20/10 mmHg of 
blood pressure, starting as low as 115/75 mmHg.4 In addition to causing coronary 
heart disease and cerebrovascular disease,  hypertension, in particular if uncontrolled, 
is the main cause of heart failure in women and the second most frequent cause in 
men, as well as a major cause of renal failure, peripheral vascular disease, and 
damage to retinal blood vessels.2  
The prevalence of diabetes was estimated to be 10% globally in 2008,1 and while it 
was once considered rare in sub-Saharan Africa,5, 6 type 2 diabetes has increased over 
the past 2 decades to the current prevalence approaching that in developed countries. 
Diabetes is associated with a 2-3 times increased risk for cardiovascular events, and 
cardiovascular diseases, including heart failure are responsible for about 60% of total 
mortality in diabetic patients.1  
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The rapid rise of hypertension, type 2 diabetes and other cardiovascular risk factors in 
sub-Saharan Africa over a fairly short period of time is attributable mainly to changes 
in lifestyle and dietary habits, which are a result of rapid urbanization and adaptation 
to western lifestyle. 
1.2 Hypertension and abnormal LV geometry 
Hypertension is a well-known cause of abnormal LV geometry, and three specific 
types of abnormal LV geometry have been described in hypertensive populations, 
based on combining LV mass indexed for body size and the ratio between wall 
thickness and internal LV chamber dimension (relative wall thickness [RWT]).7 The 
different abnormal LV geometric types have been associated with specific clinical 
and hemodynamic factors as well as individual prognostic importance.8, 9 Only about 
6 to 20% of the variability of LV muscle mass is accounted for by blood pressure.10 
Other factors such as gender, race and high dietary sodium intake, presence of other 
comorbidities like obesity, renal insufficiency, metabolic syndrome, diabetes mellitus 
as well as genetics may contribute to the increase in LV mass in hypertension in 
individual patients beyond the effect of elevated blood pressure itself.11-13 
In studies performed in the United States of America, race-associated differences in 
LV and left atrial adaptation to chronic hypertension have been described.14-16 
Particularly, LV mass, RWT and LV hypertrophy were higher among treated 
hypertensive African Americans compared to Caucasians participating in 
Hypertension Genetic Epidemiology Network study.16 Moreover, in the Dallas Heart 
Study, African Americans had higher LV mass and a 2- to 3-fold higher prevalence 
of LV hypertrophy in the general population.14 Finally, among hypertensive veterans,  
greater RWT (more concentric LV geometry) was reported in African American men 
compared to Caucasians.15  
However, results from studies on African Americans with hypertension may not 
correctly reflect findings in native hypertensive Africans who have never emigrated, 
and therefore have been exposed to quite different lifestyle, socio-economical and 
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environmental factors. Only few studies on LV structure and function have so far 
been performed in native hypertensive Africans living in sub-Saharan Africa.17-19 In 
particular, few data on untreated hypertensive patients have been published from the 
region, and only 1 previous study had included a healthy control group.18 There is 
therefore a need for additional studies on cardiac target-organ damage in hypertensive 
Africans living in sub-Saharan Africa as basis for management and awareness of this 
emerging major health problem in the region. 
1.3 Diabetes and abnormal LV geometry 
The co-existence of type 2 diabetes with other cardiovascular risk factors such as 
hypertension and obesity may contribute to the association of diabetes with higher 
prevalence of abnormal LV geometry. In the Framingham study, primarily including 
Caucasians, a significant increase in LV wall thickness was particularly seen in 
women with diabetes20 and type 2 diabetes was associated with higher LV mass and 
wall thicknesses in both men and women participating in the Strong Heart Study in 
North American Indians.21 Furthermore, in a large multiracial study of hypertensive 
patients with LV hypertrophy, concomitant type 2 diabetes was associated with less 
reduction in LV hypertrophy and less improvement in LV systolic function despite 
aggressive systematic antihypertensive treatment, suggesting impaired cardiac benefit 
from blood pressure treatment when type 2 diabetes and hypertension coexist.22 In 
patients with type 2 diabetes, insulin resistance and peripheral hyperinsulinemia is 
common, and most type 1 diabetic patients have peripheral hyperinsulinemia. Insulin 
is a known cardiovascular growth factor and insulin treatment has been associated 
with diabetes related hypertrophy in the arterial wall as well as LV hypertrophy.23, 24  
In patients with type 1 diabetes, increase in LV mass and subclinical LV dysfunction 
have been associated with diabetic nephropathy, hypertension, high dietary sodium 
intake as well as the duration of diabetes.25-27 Although atherosclerosis and 
hypertension may account for many of the myocardial abnormalities in patients with 
diabetes, a specific form of diabetic cardiomyopathy has also been described.28-30 
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Diabetic cardiomyopathy is a result from myocardial damage in diabetic patients 
caused by the metabolic changes from diabetes itself, including cardiomyocyte 
apoptosis, interstitial fibrosis and disturbances in cellular calcium homoeostasis.31 
This can echocardiographically be characterized by chamber dilatation and 
hypertrophy, as well as LV systolic and diastolic dysfunction 21, 32 and an important 
consequence of diabetic cardiomyopathy is heart failure.33  
Independent of type of diabetes, there is lack of information about the prevalence, 
covariates and functional consequences of abnormal LV geometry in diabetic 
Africans living in sub-Saharan Africa. 
1.4 Impact of abnormal LV geometry on LV function 
Following the LaPlace’s law, the LV adaptation to chronic pressure overload is an 
increase in wall thickness to reduce LV wall stress and maintain LV ejection fraction. 
However, LV adaptation to chronic pressure overload in individual hypertensive 
patients is influenced by comorbidities like diabetes, obesity, renal insufficiency and 
arterial changes as well as by gender, race and age, as depicted above.11-13 
Echocardiographic studies have demonstrated that although LV systolic chamber 
function measured by ejection fraction may be preserved in early stages of 
hypertension, LV systolic midwall function is often suppressed, particularly in 
patients with increased RWT.34 Furthermore, LV systolic function varies between 
different types of abnormal LV geometry.35, 36 This variation is not fully explained by 
gender differences or LV chamber size.35, 37 Among asymptomatic patients with mild 
hypertension, a mild to moderately reduced LV ejection fraction is found in 10% and 
a severely reduced LV ejection fraction in 3%.38 Among hypertensive patients with 
signs of LV hypertrophy on the electrocardiogram, around 14% will have reduced LV 
ejection fraction.39 
Independent of presence of abnormal LV geometry, 30-50% of patients with mild 
hypertension and up to 90% of patients with severe hypertension have signs of 
diastolic dysfunction which can be detected by echocardiography.38 With progressive 
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impairment of diastolic relaxation as part of the hypertensive heart disease, LV 
diastolic dysfunction progresses, resulting in increased LV filling pressures, with left 
atrial enlargement and diastolic heart failure, also called heart failure with preserved 
LV ejection fraction, the classical type of hypertensive heart failure. However, 
enlarged left atrium in hypertension does not solely reflect LV diastolic function, but 
is also influenced by a number of other modifiable as well as non-modifiable factors, 
including age, gender, blood pressure level, LV hypertrophy, obesity, mitral valve 
regurgitation and atrial fibrillation, as demonstrated in the multiracial Losartan 
Intervention For Endpoint reduction in hypertension echocardiography sub study.40 
Left atrial enlargement may be an early sign of hypertensive heart disease, and 
independent of presence of LV hypertrophy, left atrial enlargement has been 
associated with increased incidence of cardiovascular events and higher all-cause 
mortality.40-42 However, it has been demonstrated that African American 
hypertensives have smaller left atrial size than their Caucasian counterparts,43 which 
has further been linked to the lower incidence of atrial fibrillation in African 
Americans.44 However, only a few studies on covariates of left atrial size in native 
Africans have been published,45 and so far the relation between LA size and LV 
diastolic dysfunction among native Africans has not yet been published. 
 
2. AIM OF THE THESIS 
2.1 General Aim:  
The aim of this thesis was to determine the prevalence and functional consequences 
of subclinical abnormal LV geometry in Tanzanian out-patients with hypertension 
and diabetes referred to Muhimbili National Hospital. 
 
2.2 Specific Aims: 
1. To assess the prevalence and covariates of abnormal LV geometry in untreated 
Tanzanian patients with hypertension  
2. To determine the prevalence and covariates of abnormal LV geometry in type 
1 and type 2 diabetic patients 
3. To determine the prevalence and covariates of enlarged left atrial volume 
index (LAVI) and its relation to LV diastolic dysfunction in asymptomatic 
type 1 and type 2 diabetic patients 
 
3. METHODS 
3.1 Patient populations 
3.1.1 Study I 
All never-treated hypertensive patients who were referred to the out-patient clinic at 
the Department of Medicine, Muhimbili National Hospital between September 2009 
and May 2010 were evaluated for inclusion in this study. Patients were included if 
they were ≥18 years of age, had seated blood pressure ≥ 140/90mmHg on two 
different occasions and had never been treated for hypertension. Patients with 
concomitant cardiovascular disease (including diabetes mellitus and symptomatic 
rheumatic valvular heart disease), pregnancy induced hypertension, or symptomatic 
end stage renal disease were excluded. Of the 200 patients received during the study 
period, a total of 39 patients were excluded, 10 due to concomitant diabetes mellitus , 
6 due to symptomatic end stage renal disease and 23 patients who did not show up for 
the echocardiogram, leaving 161 (80.5%) patients available for inclusion. 
3.1.2 Studies II and III 
In studies II and III, 184 diabetic patients (123 with type 2 diabetes and 61 with type 
1 diabetes) were included. These patients were part of a prospectively planned 
follow-up examination of 244 diabetic patients who previously participated in a study 
to determine the prevalence of microalbuminuria in diabetic patients attending 
Muhimbili National Hospital in 2003-2004.46 In 2008, all 184 patients (75% of the 
original cohort) who were still receiving care at the clinic were invited to participate, 
and all agreed to participate in the present follow-up examination with 
echocardiography. For study III, LA volume could not be measured in 4 patients due 
to poor apical image windows, leaving 180 patients for that analysis. 
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3.1.3 Healthy controls 
To be able to relate findings in the hypertensive population to values found in 
normotensive Tanzanian population, a healthy control group was included in the 
project. Eighty normotensive healthy adults matched for age- and gender distribution 
with the hypertensive patients were recruited to serve as controls in study I. They 
were recruited from hospital employees, family members escorting patients as well as 
prospective kidney donors referred for routine echocardiography. Controls were 
required to have no known disease of any kind, not using any type of medication and 
have seated clinic blood pressure <140/90mmHg documented on 2 or more 
occasions. 
3.2 Clinical assessment and Laboratory tests 
Structured questionnaires were used to record the participants’ socio-demographic 
characteristics, cardiovascular risk factors and use of medications (appendices A, B, 
and C). Height, weight, waist and hip circumference were measured. Body mass 
index was calculated from body weight in kilogram divided by height in metres2 and 
obesity was considered present when body mass index was ≥ 30kg/m2.47 Waist 
circumference measured at the level of umbilicus was used as a measure of central 
adiposity.  
A mercury sphygmomanometer was used to measure blood pressure. An appropriate 
cuff size was used for each patient and measurements were done in a quiet room, with 
the patient in the sitting position after a five minutes’ rest. A set of three readings, 
five minutes apart were performed by an experienced study nurse. For analysis, the 
average of the last two readings was taken as the patient’s clinic blood pressure. 
Patients were considered as having hypertension when the clinic blood pressure was 
≥140 mmHg systolic and/or 90 mmHg diastolic.48 Hypertension was defined as 
elevated clinic blood pressure or use of antihypertensive medications in studies II and 
III.  
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Blood samples were drawn in the morning after an overnight fast and analyzed for 
creatinine, lipid profile (total cholesterol, low density and high density lipoprotein 
cholesterol) and glucose. Blood was also analyzed for glycated haemoglobin (HbA1c) 
in the diabetic patients. Biochemical tests were performed with the use of a chemistry 
analyser (Abbot Architect, Illinois, USA) at the Muhimbili National Hospital 
laboratory, while blood glucose and HbA1c were analyzed at the clinic using a 
HemoCue AB glucose analyzer (Angelholm, Sweden) and a DCA 2000+ analyser 
(Bayer Inc., New York, USA), respectively. Estimated glomerular filtration rate was 
calculated using the Cockcroft-Gault equation and was considered low when it was 
<60ml/min/1.73m2.49  
A spot early morning urine sample was collected and analyzed for albuminuria using 
the same equipment used to measure HbA1c (the DCA 2000+ analyzer). 
Microalbuminuria was defined as urine albumin to creatinine ratio (UACR) >30 mg/g 
and macroalbuminuria as UACR >300mg/g.50 Abnormal albuminuria was defined as 
UACR>30 mg/g. UACR was not tested among the healthy controls due to limited 
funding of the project. 
Metabolic syndrome was defined as the presence of any 3 of the following: elevated 
waist circumference (≥102/88cm in men/women), elevated triglycerides 
(≥1.7mmol/l), reduced high density lipoprotein cholesterol (<1.03/1.3mmol/l in 
men/women), elevated blood pressure (≥130mmHg of systolic or ≥85mmHg of 
diastolic blood pressure) or elevated fasting glucose (≥5.6mmol/l), according to the 
American Heart Association/National Heart, Lung and Blood Institute criteria.51 
3.3 Echocardiography 
3.3.1 Echocardiography study protocol 
All echocardiograms were performed by the primary investigator (PC) after receiving 
special training in echocardiography at the Non-invasive Cardiac Imaging Unit at 
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. A 
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SONOS 7500 Phillips machine equipped with a 3-MHz transducer and second 
harmonic imaging was used. The standardized echocardiographic protocol used 
included two-dimensional parasternal long- and short-axis views as well as two-, 
three- and four-chamber images of the LV and left atrium. Pulsed-wave as well as 
colour Doppler studies of LV filling were recorded. Spectral tissue Doppler of the 
mitral annular plane movement was recorded in the apical four-chamber view. 
All images were recorded on magnetic optical disks and on high resolution video 
tapes. Post processing of the digital images was done using a Tomtec (TomTec 
Imaging Systems GmbH, Unterschielssheim, Germany) work station equipped with 
Image Arena version 4.1 software. All image analysis was done at the Department of 
Heart Diseases, Haukeland University Hospital, in Bergen Norway. All studies were 
first read by the primary investigator and then proof read by the senior investigator, a 
highly experienced reader (EG). 
3.3.2  Assessment of LV geometry 
Quantitative echocardiography was performed following the American Society of 
Echocardiography guidelines.52 LV mass was calculated using the anatomically 
validated formula by Devereux.53 Due to the high prevalence of obesity among the 
study populations, LV hypertrophy was considered present when LV mass indexed 
for height2.7 exceeded the prognostically validated cut-off values of 49.2g/m2.7 in men 
and 46.7g/m2.7 in women.54, 55 RWT was calculated as the ratio of end-diastolic 
posterior wall thickness to end-diastolic LV internal radius and considered increased 
if ≥0.43. Categorization of patients into four LV geometric patterns was done based 
on LV hypertrophy and RWT measurements in combination.52 Normal geometry was 
considered present if LV mass index and RWT were both normal, concentric 
remodelling was the combination of normal LV mass index and increased RWT, 
eccentric hypertrophy the combination of LV hypertrophy and normal RWT, and 
concentric hypertrophy was considered present if LV hypertrophy and increased 
RWT were both present (Fig. 1). 
 22 
 
Fig. 1. Left ventricular geometric patterns 
 
3.3.3  Assessment of LV systolic function 
LV chamber systolic function was assessed by means of fractional shortening, stress-
corrected fractional shortening, ejection fraction and stroke volume. Fractional 
shortening was calculated as (LV end-diastolic diameter – LV end-systolic 
diameter)/LV end-diastolic diameter. Stroke volume and ejection fraction were 
calculated using biplane Simpson’s method and LV ejection fraction was considered 
low when <55%.52  
LV myocardial systolic function was assessed from midwall fractional shortening, 
calculated using a previously validated equation, taking into consideration the 
epicardial migration of the midwall during systole, as well as from stress-corrected 
midwall shortening.34 Circumferential end-systolic stress was estimated at the 
midwall using a cylindrical model.56 Stress-corrected fractional shortening and stress-
corrected midwall shortening were calculated as the ratio between the actual and 
predicted fractional shortening and midwall shortening for a given wall stress, 
 23 
respectively.34 Stress-corrected midwall shortening, a measure of myocardial 
contractility, was considered low if <87% in men and <90% in women.57 
3.3.4  Assessment of LV diastolic function 
Pulsed-wave Doppler was used for recordings of flow between the mitral leaflets tips 
in the apical four-chamber view and in the proximal LV outflow tract in the apical 
five-chamber view. The leading edge of the mitral flow pattern was traced to derive 
peak early (E) and atrial (A) velocities, the E/A ratio and E wave deceleration time. 
Isovolumic relaxation time was measured from the leading edge of the aortic valve 
closure spike to the leading edge of the mitral valve opening spike.  
Early diastolic mitral annular plane velocity (E’) was measured by spectral tissue 
Doppler from the medial annulus border in the apical four-chamber view. The ratio of 
the peak E velocity to medial mitral annulus velocity (E/E’ ratio) was used as an 
estimation of LV filling pressure58 and LV diastolic dysfunction was defined using 
the prognostically validated cut-off value E/E’ ≥15.59 
Left atrial volume was measured using biplane Simpson’s method at the end of LV 
systole and indexed to body surface area to obtain left atrial volume index (LAVI). 
LAVI was considered enlarged if  ≥29ml/m2.52 Assessment of mitral valve 
regurgitation was done using colour Doppler imaging and graded from 1 to 4 based 
on the neck width and length of the colour Doppler regurgitation.60 
3.4 Statistical methods 
Data management and statistical analysis was performed using SPSS for Windows 
version 18.0 (SPSS Inc., Chicago, Illinois, USA). Data are expressed as mean ± SD 
for continuous variables and as percentages for categorical variables. Groups of 
patients were compared using chi-square test for categorical variables and unpaired 
Student’s t-test, one-way ANOVA with Sheffe’s post hoc test or general linear model 
with Sidak’s post hoc test for continuous variables, as appropriate. Bivariate 
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correlations were assessed by Pearson’s correlation coefficient. Multivariate linear 
and logistic regression analyses were performed to determine independent predictors 
of higher LV mass index and RWT, as well as independent predictors of different 
measures of LV systolic and diastolic dysfunction. Receiver operating characteristic 
(ROC) curve analysis was used to obtain the optimal cut-off point for the prediction 
of increased RWT using the risk score formulated in study II. ROC analysis was also 
used to compare the relation of LV hypertrophy and LAVI with presence of diastolic 
dysfunction in study III, reporting area under the curve and 95% confidence intervals. 
Area under the curves were compared by DeLong’s test61 using MedCalc software 
version 12.1.3 (MedCalc, Mariakerke, Belgium). A two-tailed p-value of ≤0.05 was 
considered statistically significant.   
 
3.5 Ethical considerations 
The project was performed in accordance with the Helsinki declaration. Ethical 
approval for the studies was obtained from the Muhimbili University of Health and 
Allied Sciences’ research and publication committee (Appendix D) and all 
participants signed a written informed consent form (Appendix E). 
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4. RESULTS 
4.1 Study I 
Prevalence and covariates of abnormal left ventricular geometry in untreated 
hypertensive patients in Tanzania 
 
In this study, 161 untreated hypertensive adults (mean age 52.5 years, 60% women) 
and 80 healthy controls (mean age 46.6 years, 56% women) were studied. 
Hypertensive patients had mean blood pressure of 166/102±21/11mmHg while the 
mean blood pressure of the controls was 121/75±13/9 mmHg (p<0.001). Patients also 
had higher body mass index, waist circumference, heart rate, serum creatinine and 
lower creatinine clearance (all p<0.05). Obesity (body mass index ≥30kg/m2) was 
present in 37% of patients and 20% of controls (p<0.01). Patients were more likely to 
have the individual components of the metabolic syndrome (Fig. 2). Fifty four 
percent of the patients and 10% of the controls met the criteria for the diagnosis of 
metabolic syndrome (p<0.001) (Fig. 2). In the total population, metabolic syndrome 
was more common in participants with abnormal LV geometry (52.7%) when 
compared to those with normal geometry (28.2%, p<0.001). When analyses were 
done separately for patients and controls, this difference was only seen among 
controls (prevalence of metabolic syndrome 40% in controls with abnormal LV 
geometry vs. 5.7% in controls with normal geometry, p<0.01) but not among patients 
(54.1% vs. 54.0%, respectively).  
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In total, 62.1% of patients had abnormal LV geometry, predominantly LV 
hypertrophy. LV geometry differed significantly between patients and controls, 
p<0.001 between groups (Fig. 3). Among controls, abnormal LV geometry was found 
in 12.5% and in all, but 1 subject this was of the concentric remodelling type while 
eccentric LV hypertrophy was found in 1 (1.2%) control subject who was also obese.  
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LV internal diameters as well as posterior-, septal-, and RWT were all significantly 
larger in patients (all p<0.01). Consequently, LV mass (192±74 vs. 121±32 g) and 
LV mass index (55.0±21.7 vs. 32.0±7.1 g/m2.7) were both higher in patients when 
compared to controls, respectively (both p<0.001). 
LV chamber systolic function measured as LV ejection fraction was lower in patients 
than in the controls (63% vs. 66%, p<0.01). LV myocardial contractility measured as 
stress corrected midwall shortening was also lower in patients than in controls (84% 
vs. 99%, p<0.001). The prevalences of impaired LV myocardial contractility 
(measured as low stress-corrected midwall shortening) and subnormal LV ejection 
fraction (<55%) were both higher in patients than in controls (Fig. 4).  
 28 
 
The prevalence of low stress-corrected midwall shortening was higher in patients 
with abnormal LV geometry when compared to patients with normal LV geometry 
(80% vs. 14.8%, p<0.001). Similarly, among controls with abnormal LV geometry, 
low stress-corrected midwall shortening was present in 70%, but only in 10% of 
controls with normal LV geometry (p<0.001).  
Patients had longer E wave deceleration time, isovolumic relaxation time and lower 
E/A ratio as well as lower early tissue Doppler velocity (E’) and higher E/E’ ratio (all 
p<0.001). LV diastolic dysfunction (measured as E/E’ ratio ≥15) was 3.3 times more 
common in patients than in controls (Fig. 4). Among the 5 controls with LV diastolic 
dysfunction, all but 1 were obese women aged 60 years or above. Among patients, 
LV diastolic dysfunction was twice as common in those with abnormal LV geometry 
compared to those with normal LV geometry (26.7% vs. 11.7%, p<0.05). In the total 
population, higher LV mass index correlated with lower stress-corrected midwall 
shortening and higher E/E’ ratio (Fig. 5). 
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In patients, abnormal albuminuria was present in 29.3%, and was more common in 
patients with abnormal LV geometry when compared to those with normal geometry 
(39.1% vs. 13.2%, p<0.01). Patients with impaired LV myocardial contractility were 
more likely to have combined abnormal LV geometry and abnormal albuminuria 
(35.9% vs. 8.6%, p<0.001), and the prevalence of both abnormal albuminuria and 
abnormal LV geometry increased with increasing severity of hypertension (Fig. 6). 
 30 
 
 
In multivariate analysis involving the total population (multiple R2 = 0.60, p<0.001), 
higher systolic blood pressure (β = 0.28, p<0.001), body mass index (β = 0.20, 
p<0.01), E/E’ ratio (β = 0.16, p<0.01) and lower stress-corrected midwall shortening 
(β= -0.44, p<0.001) as well as estimated glomerular filtration rate (β = -0.16, p<0.05) 
were all independently associated with higher LV mass index. Similar findings were 
obtained when the analysis was performed in the patient group only. In addition, 
replacing estimated glomerular filtration rate with abnormal albuminuria in a second 
multivariate model including only the patients, revealed that abnormal albuminuria (β 
= 0.17, p<0.01) was independently associated with higher LV mass index. The 
independent covariates of higher RWT (i.e. concentric LV geometry) in the total 
population were higher systolic blood pressure (β = 0.16, p<0.01), E wave 
deceleration time (β = 0.23, p<0.001), and lower stress-corrected midwall shortening 
(β = -0.66, p<0.01) (multiple R2 = 0.55, p<0.001). In an additional model, higher 
body mass index (β = 0.14, p<0.05) was independently associated with higher RWT 
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within the patient group. Neither age nor gender predicted abnormal LV geometry in 
this population.  
4.2 Study II  
Increased relative wall thickness is a marker of subclinical cardiac target organ 
damage in African diabetic patients 
In order to assess the prevalence of abnormal LV geometry among Tanzanian 
diabetic patients, 123 type 2 (mean age 55 years, 65% women) and 61 type 1 (mean 
age 22 years, 55% women) asymptomatic diabetic patients were studied. Type 2 
diabetic patients had longer duration of diabetes (10.7 vs. 8.2 years) and included 
more hypertensive (82% vs. 18%) and obese (36.6% vs. 3.3%) patients (all p<0.01). 
Type 2 diabetic patients had larger LV dimensions, higher RWT, LV mass index as 
well as lower stress-corrected midwall shortening and impaired LV relaxation 
evidenced by lower E/A ratio, longer deceleration and isovolumic relaxation time (all 
p<0.05). In the total population low ejection fraction was present in 3.8%, and it was 
not statistically different between type 1 (1.6%) and type 2 (4.9%) diabetic patients, 
p=0.280. The prevalence of low stress-corrected midwall shortening was significantly 
higher in type 2 diabetic patients (74.8% vs. 39.3%, p<0.001). Patients with type 2 
diabetes had higher E/E’ ratio and were more likely to have LV diastolic dysfunction 
when compared to type 1 diabetic patients (20.5% vs. 3.5%), p<0.01.  
 
LV geometry differed significantly among type 1 and type 2 diabetic patients (Fig. 7). 
The most common abnormal LV geometric pattern in type 2 diabetic patients was 
concentric LV hypertrophy, while concentric remodelling was the most common 
abnormal LV geometric pattern in type 1 diabetic patients (Fig. 7).  
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Overall, 58% of the total diabetic population had increased RWT, synonym with 
concentric LV geometry. The most important correlates of higher RWT were older 
age (r = 0.36 for type 1, r = 0.20 for type 2), higher systolic blood pressure (r = 0.36 
for type 1, r = 0.23 for type 2) and more abnormal albuminuria (r = 0.26 for type 1, r 
= 0.19 for type 2), all p<0.05. In addition, lower estimated glomerular filtration rate (r 
= -0.32) and high density lipoprotein cholesterol (r = -0.28) significantly correlated 
with higher RWT among type 2 diabetic patients, but not in type 1. Having increased 
RWT was also associated with impaired systolic and diastolic LV function including 
lower myocardial contractility measured as stress-corrected midwall shortening, and 
delayed early LV diastolic relaxation measured as longer isovolumic relaxation time, 
longer deceleration time and reduced E/A ratio, both in type 1 and type 2 diabetic 
patients (all p<0.05). Multivariate linear regression analysis in the total population 
(multiple R2 = 0.69, p<0.001) identified higher systolic blood pressure (β = 0.30), 
longer isovolumic relaxation time (β = 0.17), low stress-corrected midwall shortening 
(β = 0.24) as well as lower circumferential end-systolic stress (β = -0.58) as 
independent covariates of higher RWT (all p<0.05). These covariates remained 
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significant when separate analyses were performed in type 1 and type 2 diabetic 
patients, and in addition low estimated glomerular filtration rate (β = 0.15, p<0.05) 
was identified as an additional independent covariate of higher RWT in type 2 
diabetic patients. 
  
In binary logistic regression analysis, the independent covariates of increased RWT 
were found to be type 2 diabetes, presence of abnormal albuminuria, obesity and 
hypertension (all p<0.05). A risk score was calculated based on the beta coefficients 
in this model. This risk score had a positive predictive value of 76% (3 out of 4 
patients) for identifying diabetic patients with abnormal LV geometry of either 
concentric remodelling or concentric LV hypertrophy type. Following this risk score, 
a patient with type 2 diabetes with any of the other three risk factors (obesity, 
hypertension or abnormal albuminuria), or a type 1 diabetic patient having any two of 
these additional cardiovascular risk factors would have a 76% chance of having 
cardiac target organ damage. 
4.3 Study III 
Left atrial volume index as a marker of left ventricular diastolic dysfunction in 
asymptomatic Tanzanian diabetic patients 
To determine the prevalence of left atrial enlargement and its relation to LV diastolic 
dysfunction, 122 type 2 and 58 type 1 diabetic patients were studied. In the total 
population, enlarged LAVI was present in 38.3%. Enlarged LAVI was more common 
among type 2 diabetic patients (44.3% vs. 25.9%, p<0.05). Patients with enlarged 
LAVI were older when compared to patients with normal LAVI both in type 1 (26.9 
vs. 18.7 years) and type 2 (56.8 vs 53.1 years) diabetic patients (both p<0.05). LV 
diastolic dysfunction (defined as E/E’ ratio ≥15) was present in 15.1% of the total 
population and was more common in type 2 than in type 1 diabetic patients (20.5% 
vs. 3.5%, p<0.01). Diabetic patients with concomitant hypertension and those with 
increased E/E’ ratio were more likely to have enlarged LAVI as well, especially 
among type 2 diabetic patients (Fig. 8).  
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In bivariate correlations, larger LAVI was significantly associated with higher 
systolic blood pressure, mean blood pressure, serum creatinine, LV mass index as 
well as higher E/E’ ratio both in type 1 and type 2 diabetic patients (all p<0.05). In 
multivariate linear regression analyses, larger LAVI was independently associated 
with having LV diastolic dysfunction (β = 0.20), higher LV mass index (β = 0.23) 
and presence of mitral regurgitation (β = 0.25) in type 2 (all p<0.05), while larger 
LAVI was independently associated with higher LV mass index (β = 0.30), lower 
ejection fraction (β = -0.37) and longer duration of diabetes (β = 0.27) in type 1 
diabetic patients (all p<0.05). In logistic regression analysis, enlarged LAVI was 
associated with a 3.3 times higher prevalence of LV diastolic dysfunction (95% 
confidence intervals 1.19 – 8.99, p<0.05) in the overall population independent of LV 
hypertrophy, type 2 diabetes and hypertension. Plotting the overall probability of this 
model with and without inclusion of LV hypertrophy among the covariates in a 
receiver operating characteristic curve demonstrated that the association between 
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larger LAVI and presence of LV diastolic dysfunction was independent of presence 
of LV hypertrophy. 
5. DISCUSSION 
5.1 Abnormal LV geometry in hypertension 
LV hypertrophy is a common complication to chronic arterial hypertension, present 
in about 20 – 60% of uncomplicated hypertension and its prevalence increases with 
increasing grade of hypertension and presence of comorbidities, as also confirmed by 
the present studies in native sub-Saharan Africans. LV hypertrophy is a well-known 
marker of subclinical cardiovascular disease, often referred to as cardiac target organ 
damage, and is associated with 2-3 times increased cardiovascular morbidity and 
mortality, including stroke, myocardial infarction, heart failure, atrial fibrillation and 
sudden cardiac death.62-67 Moreover, the type of LV geometric patterns adds 
prognostic information beyond that of LV mass or hypertrophy alone.8, 9, 68, 69 The 
present thesis adds to current knowledge of cardiac target organ damage in native 
Africans with hypertension by demonstrating a high prevalence (62%) of abnormal 
LV geometry in asymptomatic, never-treated Tanzanian patients with hypertension 
referred for out-patient evaluation at Muhimbili National Hospital, in Dar es Salaam, 
Tanzania. The prevalence was 5 times higher than that found in the age- and gender-
matched controls. Of note, LV hypertrophy was present in 52.8% of patients as 
opposed to 1.2% in controls.  
 
The high prevalence of abnormal LV geometry found among never-treated Tanzanian 
hypertensive patients in the present project is in line with previous echocardiographic 
studies in hypertensive African Americans despite differences in lifestyle and 
comorbidities,15, 16, 70 as well as previous studies in native Africans.18, 19 Only a few 
echocardiographic studies have so far been published from hypertensive Africans 
living in sub-Saharan Africa. In a study of 100 untreated hypertensive Nigerians by 
Aje et al.,18 abnormal LV geometry was found in  72%, while abnormal LV geometry 
was reported in 83% in a recent echocardiographic study of mostly treated 
hypertensive South African patients participating in the Baragwanath Hypertension 
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Study.19 The differences in prevalence between the present and these previous 
African studies could be due to differences in level of blood pressure between the 
study participants but also presence of comorbidities. Although both the present study 
and that by Aje et al. excluded patients with comorbidities, more patients with 
subclinical renal impairment may have contributed to the higher prevalence of  
abnormal LV geometry seen in the study by Aje et al., but assessment of renal 
function was not included in their study.18 On the other hand, the study by Libhaber et 
al. included patients who were previously treated hypertensives and therefore more 
likely to have longer duration of hypertension resulting in more target organ 
damage.19 Worth a mention here though, is the finding of almost similar prevalences 
of abnormal LV geometry in the control groups in the present study and in the study 
by Aje et al.18 In their study, the prevalence of concentric remodelling, eccentric 
hypertrophy and concentric hypertrophy among the controls was 11%, 3% and 0%, 
respectively while the corresponding prevalences were 11.3%, 1.2% and 0% in the 
present study. High prevalence of concentric remodelling has been reported also in 
normotensive African Americans participating in the Atherosclerotic Risk in 
Communities study.71  
 
In bi- or multiracial echocardiographic studies performed in the United States of 
America, higher LV walls and mass have been found in African Americans when 
compared to Caucasians, both in hypertensive15, 16 and in general population 
studies.14, 72 The differences in LV mass and geometry between African Americans 
and Caucasians have been attributed to differences in lifestyle and socio-economical 
factors influencing comorbidities, treatment adherence and risk for renal or 
cardiovascular complications, but also race-associated increase in LV mass has been 
suggested.73 In the Genetic Epidemiology Network of Arteriopathy Study that 
involved a cohort of hypertensive Caucasians and African American siblings, genetic 
variation that significantly influenced LV mass index as well as RWT was 
identified.74 From this, the high prevalence of abnormal LV geometry also 
demonstrated in the present study among hypertensive patients in sub-Saharan Africa 
may be partly genetically explained. However, the prevalence of abnormal LV 
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geometry paralleled the severity of hypertension, increasing from 46% among 
patients with mild hypertension to 67% among those with moderate and 81% among 
those with severe hypertension, suggesting that independent of genetic impact on LV 
mass in Africans, presence and severity of a modifiable predictor like blood pressure 
has a substantial impact on the presence of cardiac target organ damage.  
 
This study found that both impaired kidney function measured as low estimated 
glomerular filtration rate and abnormal albuminuria, indicating reduction in or 
damage to renal glomeruli, respectively, were independently associated with higher 
LV mass, in line with previous studies.13, 75, 76 Of particular interest is the finding that 
abnormal albuminuria was independently associated with presence of LV 
hypertrophy independent of blood pressure, body mass index, age or gender. This is a 
clinically important finding, as a simple test of abnormal albuminuria could be used 
in identifying hypertensive patients at an increased risk of LV hypertrophy as well as 
identifying patients at increased risk of subsequent heart failure, as reported earlier.77, 
78  However, as demonstrated by our results, abnormal albuminuria was only present 
in 18.5 to 43.6% of patients depending on the severity of hypertension, and among 
patients with abnormal LV geometry, abnormal albuminuria was present in 39.1%. 
Thus, assessing albuminuria in a spot urine sample alone cannot substitute 
echocardiography in identification of cardiac target organ damage in native African 
patients with essential hypertension. Again, the study findings demonstrated that 
prevalence of abnormal albuminuria as a marker of renal hypertensive target organ 
damage increased in parallel with the severity of hypertension. Previous studies have 
demonstrated reduction in albuminuria and prevention of renal failure by 
antihypertensive treatment in hypertensive patients.79, 80 
 
Contrasting findings in previous studies from the United States of America and Italy 
which showed that presence of the metabolic syndrome is strongly related to 
abnormal LV geometry in patients with hypertension,11, 12, 81 the present study did not 
find a statistically significant association between presence of metabolic syndrome 
and abnormal LV geometry in the present study. Among hypertensive patients the 
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prevalence of metabolic syndrome was identical in those with and without abnormal 
LV geometry, suggesting that the presence of metabolic syndrome did not influence 
LV geometry in this study. However, the finding that higher body mass index was 
independently associated with both LV mass and RWT is in keeping with many 
previous studies both from hypertensive and general populations including African 
Americans as well as Caucasians.11, 15, 70, 82, 83 These findings further emphasize the 
need to control overweight and obesity in patients with hypertension. 
 
5.2 Abnormal LV geometry in diabetes 
Previous publications from the Strong Heart Study in North American Indians have 
reported that LV mass and prevalence of LV hypertrophy are higher in diabetic 
subjects, in particularly if diabetes and hypertension co-exist.84, 85 In the present 
studies 77% of type 2 and 40% of type 1 diabetic patients had abnormal LV geometry 
approximately 10 years after the diagnosis of diabetes. Concentric remodelling and 
concentric LV hypertrophy (i.e. concentric LV geometry) were the most common 
types of abnormal LV geometry. Only few echocardiographic studies have so far 
been performed in native sub-Saharan African type 2 diabetic patients while no study 
on type 1 diabetic patients has previously been reported from the region.86 Therefore, 
the findings of these studies add to previous knowledge about subclinical diabetic 
heart disease in Africans in the sub-Saharan region. 
 
The effect of diabetes, especially type 2 diabetes, on LV geometry has been well 
documented in North American Indians as well as in a population sample of 
hypertensive adults participating in the HyperGEN study.84, 85 In these studies, type 2 
diabetes alone was associated with higher LV mass and RWT compared to subjects 
without diabetes or hypertension and highest levels of LV mass and wall thicknesses 
were found when type 2 diabetes co-existed with hypertension, indicating that 
diabetes has an additive effect on LV mass and wall thickness on top of the effect of 
blood pressure. However, the prevalence of LV hypertrophy by echocardiography 
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was 38% among patients with combined type 2 diabetes and hypertension in both 
these studies,84, 85 demonstrating a much higher prevalence of LV hypertrophy in the 
present study (44% combined eccentric and concentric LV hypertrophy) reflecting 
cardiac effects of diabetes in sub-Saharan Africans. Furthermore, in a recent 
echocardiographic study of normotensive type 2 diabetic Nigerians by Ojji et al., 
abnormal LV geometry was found in 51%86 which is much lower than the 77% 
prevalence obtained in the mostly hypertensive type 2 diabetic patients participating 
in the current project. 
 
The deleterious effect of hypertension on LV structure in diabetes is also 
demonstrated by the difference in LV geometry between type 2 and type 1 diabetic 
patients in the present project. Of note, hypertension was present in 82% in type 2 
and 18% of the type 1 diabetic patients and systolic blood pressure was the main 
independent determinant of higher RWT in the total population and also within the 
type 1 and type 2 diabetic patient groups. However, patients with type 2 diabetes in 
this study were also older, had higher body mass index and longer duration of 
diabetes, all known factors that are associated with increase in LV mass in patients 
with diabetes.84, 85 Our finding that concentric LV geometry was the predominant 
abnormal LV geometry is in agreement with findings from the HyperGEN study as 
well as the Strong Heart study, although these studies mostly included type 2 diabetic 
patients.84, 85 
 
While the prevalence of hypertension was relatively low in the young type 1 diabetic 
patients in this cohort, prevalence of abnormal albuminuria was high, present in 40%. 
Renal impairment and abnormal albuminuria reflecting nephropathy in patients with 
diabetes are associated with cardiac target-organ damage as well as cardiovascular 
morbidity and mortality. In the present study, although including only asymptomatic 
patients without known cardiovascular disease or renal failure as assessed by 
estimated glomerular filtration rate, renal function was associated with concentric LV 
geometry only among type 2 diabetic patients. In contrast, within type 1 diabetic 
patients, no statistically significant association between lower kidney function and 
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higher RWT was found. Experimental studies have demonstrated that hyperglycemia 
promotes increased production of reactive oxygen species and collagen type 1 and II, 
promoting cardiomyocyte apoptosis as well as interstitial fibrosis.31  Furthermore, 
changes in cellular calcium homoeostasis leading to both systolic and diastolic 
dysfunction have been described in experimental studies of diabetes in rodent 
models.31 In particular altered expression, activity and function of key calcium 
transporters involved in excitation contraction coupling like SERCA (sarcoplasmatic 
endoplasmatic reticulum calcium ATPase), NCX (sarcolemma natrium-calcium 
exchange) and PMCA (plasma membrane calcium ATPase) have been demonstrated 
in these rodent studies.31 From this, a disproportionate reduction in LV systolic 
function in relation to LV mass would be expected in diabetes. Indeed, this was 
reported in the echocardiographic substudy of the large Losartan Intervention For 
Endpoint reduction in hypertension study, as well as a reduced regression of LV 
hypertrophy and less improvement in LV systolic function following systematic 
antihypertensive treatment independent of type of drug.22   
 
Diabetic patients with nephropathy have increased blood volume and body sodium 
and are often more likely to have hypertension and an exaggerated sympathetic 
nervous system as well as the rennin-angiotensin-aldosterone system, all factors that 
may explain the increase in LV mass associated with nephropathy.87-89 In type 1 
diabetes, nephropathy and duration of diabetes are causally associated with 
development of hypertension, while hypertension often precedes diagnosis of type 2 
diabetes.27, 87, 88, 90    
 
In the present project, we found body mass index to correlate with concentric LV 
geometry in the total diabetic population, but obesity did not predict presence of 
concentric LV geometry in multivariate analysis, contrasting other reports.70, 83 
However, our finding that obesity was associated with LV hypertrophy is in 
agreement with studies from others.15, 71 Furthermore, both obesity and diabetes are 
associated with sympathetic activation, insulin resistance, hyperglycemia and 
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peripheral hyperinsulinemia which together with hypertension are among the main 
mechanisms inducing LV hypertrophy in such patients.91  
 
5.3 Functional consequences of abnormal LV geometry 
Independent of presence of abnormal LV geometry, 30-50% of patients with mild 
hypertension and up to 90% of patients with severe hypertension have signs of 
diastolic dysfunction which can be detected by echocardiography.38 However, LV 
systolic function, whether measured as LV ejection fraction or as stress-corrected 
midwall shortening, is influenced by LV geometry in patients with hypertension as 
well as chronic pressure overload due to aortic valve stenosis.35-37  
 
As demonstrated by the multivariate analysis in the present project,  lower stress-
corrected midwall shortening was particularly associated with increased RWT, 
independent of LV mass index, confirming findings in other studies that concentric 
LV geometry is especially associated with depressed myocardial contractility.39 In a 
study of 960 hypertensive patients with electrocardiography LV hypertrophy by 
Wachtell et al., subnormal LV ejection fraction was present in 14% and low stress-
corrected midwall shortening in 26%.39 The prevalence of echocardiographic LV 
hypertrophy was 70% in that study which predominantly included Caucasians, the 
majority previously treated with antihypertensive drugs. While the prevalence of 
subnormal LV ejection fraction was lower in the study by Wachtell et al.,39 the 
prevalence of depressed LV myocardial contractility was higher in the present study 
which demonstrated low LV ejection fraction in 21.7% and low stress-corrected 
midwall shortening in 55.3%, indicating an overall more depressed LV systolic 
function in our never-treated patients despite being on average 10 years younger, free 
of concomitant type 2 diabetes and despite having lower prevalence of abnormal LV 
geometry.  
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Both subnormal LV ejection fraction and stress-corrected midwall shortening predict 
incident heart failure as well as cardiovascular outcome independent of LV mass and 
clinical risk factors in large randomized trials as well as in prospective observational 
studies.92, 93 Of interest though is the finding that LV midwall systolic performance 
significantly improved during effective antihypertensive treatment, following 
reduction in LV mass and hypertrophy in a study by Muiesan et al.94 However, in 
hypertensive patients with concomitant type 2 diabetes, the cardiac benefit following 
systematic aggressive antihypertensive treatment was attenuated, including less 
reduction in LV mass and less improvement in systolic function even after 4-5 years 
of treatment.22 Furthermore, in severely obese hypertensive patients, residual LV 
hypertrophy was present in 70% of treated hypertensive patients, explaining the high 
cardiovascular event rate in such patient, in particular hospitalization for heart failure 
and cardiovascular death.95, 96 
 
Concentric LV geometry has been particularly associated with impaired LV 
relaxation and diastolic dysfunction. The finding that concentric LV geometry was 
independently associated with longer E wave deceleration time is in agreement with 
findings from the HyperGEN study which found that the odds of having abnormal 
LV relaxation were 2.3-fold greater when LV geometry was concentric.97 In the 
present project, LV diastolic function was assessed by echocardiography using 
combination of LV filling pressure, early diastolic mitral annulus velocity and left 
atrial size. Several of these measures have prognostic value as demonstrated in 
previous publications, including mitral deceleration time index, E/A ratio, E/E’ ratio 
and left atrial size.98, 99 In patients with electrocardiographic LV hypertrophy, 
antihypertensive treatment resulted in significant improvement in transmitral flow 
patterns, and although this change was not associated with reduced cardiovascular 
morbidity and mortality, it was associated with reduced risk of hospitalization for 
heart failure.100  
 
From the South African Heart of Soweto study it was previously reported that among 
Africans hospitalized with congestive heart failure hypertension, diabetes and obesity 
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were present in >80% of patients.101 Furthermore, pure diastolic heart failure was 
found in 23%, and particularly associated with diabetes. The present studies add to 
this knowledge by a much more detailed assessment of LV structure and systolic and 
diastolic function in asymptomatic diabetic patients. In particular, diastolic 
dysfunction was found in 20.5% of type 2 diabetic patients in the present study, and 
associated with co-existing hypertension, while diastolic dysfunction was rare among 
type 1 diabetic patients.    
5.4 Can abnormal LV geometry be predicted from clinical 
variables? 
Presence of abnormal LV geometry signifies for the individual hypertensive patient a 
very high risk for cardiovascular events including heart failure, stroke, myocardial 
infarction and sudden cardiac death.48 Particularly in hypertensive patients with 
moderately elevated blood pressure or few additional cardiovascular risk factors, 
identification of hypertensive target organ damage significantly changes the 
recommended management by the guidelines.48 An important question is whether 
abnormal LV geometry in patients with hypertension and diabetes can be predicted 
from daily clinical variables in a setting like Tanzania where echocardiograph is not 
readily available. In patients with hypertension, use of single urine albumin test can 
identify patients at increased risk of LV hypertrophy as abnormal albuminuria was 
found to independently predict higher LV mass index in the hypertensive population. 
However, and as pointed out earlier, measurement of abnormal albuminuria cannot 
replace echocardiography as abnormal albuminuria was only present in 39.1% of 
patients with abnormal LV geometry. These findings are in line with previous 
findings in a large multiracial study of hypertensive patients with 
echocardiographically determined LV hypertrophy, reporting a prevalence of 
abnormal albuminuria of 33%.75  
The level of blood pressure at presentation can however give a better indication of the 
presence of abnormal LV geometry. As demonstrated by our results, patients with 
stage II and III of hypertension were more likely to have abnormal LV geometry, and 
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among patients with severe hypertension, 81% had abnormal LV geometry on the 
echocardiogram.  
As demonstrated, in patients with type 2 diabetes, presence of either of obesity, 
hypertension or albuminuria increased the chance that the patient will also have 
abnormal LV geometry to 76%, while for type 1 diabetic patients, presence of two of 
these factors indicated a 76% probability of having abnormal LV geometry.  
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6. Limitations 
Some important study limitations should be mentioned. Although this project used 
more standardized and advanced echocardiography than previous publications on 
hypertensive and diabetic cardiac target organ damage on native sub-Saharan 
Africans, a limited number of patients and controls were studied. Further studies in 
more rural settings would add potential scientific and clinically important knowledge.  
 
Furthermore, deformation analysis including strain and strain rate was not used, as 
this was not available on the provided echocardiograph at Muhimbili National 
Hospital. Adding deformation analysis is useful to detect subclinical LV dysfunction 
in patients despite normal LV ejection fraction.102 However, beyond LV ejection 
fraction, we assessed midwall function with prognostically validated measures in 
hypertensive populations,92 including midwall shortening and stress-corrected 
midwall shortening which hypothetically may be closely associated with global 
longitudinal strain. 
 
Ambulatory blood pressure measurement was not available. White coat hypertension 
could therefore not be excluded from the hypertensive group. However, given the 
high prevalence of target organ damage, it is highly unlikely that white coat 
hypertension was prevalent among the patients. We can also not exclude that one or 
more control subjects may have been hypertensive despite normal office blood 
pressure on at least two visits, or that diabetic patients may have been misclassified. 
Such errors would lead to an underestimation of the true impact of hypertension on 
subclinical target-organ damage in native Africans.  
 
Dietary salt intake is known to affect blood pressure as well as hypertensive cardiac 
and renal complications in particular in Africans.103 Dietary salt intake can be 
measured in collected 24 hour urine samples or from standardized dietary 
questionnaires. The present project did not include measurement of daily salt intake 
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due to the complexity of these methods which were not available within the setting at 
the out-patient clinic.  
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7. Perspectives 
The results of this thesis provide an insight to the burden of cardiac target-organ 
damage in native African patients with hypertension and diabetes attending care at a 
referral hospital. These results should be used as a tool in creating awareness, first at 
the institution level but also at the national level regarding the burden of hypertensive 
and diabetic heart disease in such patients. The results should together with WHO 
recognition of hypertension among the three most important health problems in 
Africa, inspire development of strategies for cardiovascular prevention in Tanzania. 
Although echocardiographic assessment of cardiac target organ damage is not 
feasible within such a strategy, measurement of blood pressure is. Indeed presence of 
concomitant hypertension in type 2 diabetes and presence of severe hypertension in 
non-diabetic hypertensive patients was the best predictor of presence of cardiac target 
organ damage in this project. 
 
Future studies should focus on the pathophysiology of LV hypertrophy and abnormal 
LV geometry among native Africans and particularly focus on determining why such 
target-organ damage is very prevalent in native Africans. Long term follow up studies 
on patients with hypertension and diabetes are also recommended so as to confirm the 
prognostic importance of abnormal LV geometry demonstrated in previous studies in 
other races also in native African patients.   
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8. Conclusions 
The aim of this thesis was to determine the prevalence and functional consequences 
of subclinical abnormal LV geometry in Tanzanian out-patients with hypertension 
and diabetes referred to Muhimbili National Hospital. The following conclusions 
were found for the pre-specified aims:  
 
Study 1: To assess the prevalence and covariates of abnormal LV geometry in 
untreated Tanzanian patients with hypertension 
The prevalence of abnormal LV geometry was 62.1% in untreated native Tanzanian 
patients with hypertension, 5 times higher than in age- and gender- matched 
normotensive controls. Higher systolic blood pressure, body mass index and presence 
of abnormal albuminuria were the main determinants of abnormal LV geometry. 
Presence of abnormal LV geometry was associated with subclinical LV systolic and 
diastolic dysfunction.   
 
Study 2: To determine the prevalence and covariates of abnormal LV geometry 
in type 1 and type 2 diabetic patients 
The prevalence of abnormal LV geometry was 77% in type 2 and 40% in type 1 
diabetic patients attending care at Muhimbili diabetic out-patient clinic. Concomitant 
hypertension and higher systolic blood pressure greatly influenced the presence of 
abnormal LV geometry both in type 1 and type 2 diabetic patients, and in the total 
population obesity and abnormal albuminuria were particularly associated with LV 
hypertrophy. Presence of abnormal LV geometry was associated with subclinical LV 
systolic and diastolic dysfunction. 
 
Study 3: To determine the prevalence and covariates of enlarged left atrial 
volume index (LAVI) and its relation to LV diastolic dysfunction in 
asymptomatic type 1 and type 2 diabetic patients 
The prevalence of enlarged LAVI was 44.3% in type 2 and 25.9% in type 1 
asymptomatic diabetic patients attending care at Muhimbili diabetic out-patient 
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clinic. In type 2 diabetic patients, enlarged LAVI independently predicted presence of 
LV diastolic dysfunction, while in type 1 diabetic patients, enlarged LAVI was 
associated with lower systolic function and longer duration of diabetes, but not with 
presence of LV diastolic dysfunction.  
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